Inventor · disambiguated record
Sheng Cui
Also filed as: CUI SHENG
15 granted patents·13 pending applications·85 citations·filing 2009–2025
92Inventor score
Top patents by PatentIndex Score
28 records- 0196US11958809B2Salt of omecamtiv mecarbil and process for preparing saltCYTOKINETICS INC·Filed 2021·Granted Apr 16, 2024·10 cites·5 claims
- 0296US11472773B2Salt of omecamtiv mecarbil and process for preparing saltAMGEN INC·Filed 2020·Granted Oct 18, 2022·17 cites·20 claims
- 0394US12221417B2Salt of omecamtiv mecarbil and process for preparing saltCYTOKINETICS INC·Filed 2023·Granted Feb 11, 2025·2 cites·4 claims
- 0494US9988354B2Salt of omecamtiv mecarbil and process for preparing saltAMGEN INC·Filed 2014·Granted Jun 5, 2018·24 cites·7 claims
- 0593US11465969B2Salts and crystal forms of omecamtiv mecarbilAMGEN INC·Filed 2019·Granted Oct 11, 2022·16 cites·32 claims
- 0692US11926592B2Salts and crystal forms of omecamtiv mecarbilAMGEN INC·Filed 2022·Granted Mar 12, 2024·8 cites·21 claims
- 0790US2025243163A1Salt of omecamtiv mecarbil and process for preparing saltCYTOKINETICS INC·Filed 2024·Application pending·0 cites
- 0887US12006305B2Salts of obicetrapib and processes for their manufacture and intermediates thereofNEWAMSTERDAM PHARMA B V·Filed 2023·Granted Jun 11, 2024·5 cites·27 claims
- 0982US2023044617A1Salt of omecamtiv mecarbil and process for preparing saltCYTOKINETICS INC·Filed 2022·Application pending·0 cites
- 1081US10407464B2Method for preparing AMG 416AMGEN INC·Filed 2015·Granted Sep 10, 2019·2 cites·14 claims
- 1177US12378221B2Salts of obicetrapib and processes for their manufacture and intermediates thereofNEWAMSTERDAM PHARMA B V·Filed 2024·Granted Aug 5, 2025·0 cites·22 claims
- 1272US2020079736A1Salt of omecamtiv mecarbil and process for preparing saltAMGEN INC·Filed 2019·Application pending·0 cites
- 1371US2024199550A1Salts and crystal forms of omecamtiv mecarbilAMGEN INC·Filed 2024·Application pending·0 cites
- 1469US2023099078A1Method for preparing amg 416 (etelcalcetide)AMGEN INC·Filed 2022·Application pending·0 cites
- 1569US2018312469A1Salt of omecamtiv mecarbil and process for preparing saltAMGEN INC·Filed 2018·Application pending·0 cites
- 1666US11377474B2Method for preparing AMG 416 (etelcalcetide)AMGEN INC·Filed 2019·Granted Jul 5, 2022·0 cites·14 claims
- 1764US9869422B2Method for preparing bulk C—AlN composite aerogel with high strength and high temperature resistanceNANJING UNIVERSITY OF TECHNOLOGY·Filed 2013·Granted Jan 16, 2018·1 cites·7 claims
- 1861US2025170128A1Obicetrapib and SGLT2 Inhibitor CombinationNEWAMSTERDAM PHARMA B V DUTCH CHAMBER OF COMMERCE NO 5597 1946·Filed 2022·Application pending·0 cites
- 1957US2024307374A1Formulation of furin inhibitor for inhalationBP ASSET V INC·Filed 2022·Application pending·0 cites
- 2056US12441741B2Ring closing synthesis of macrocyclic MCL-1 inhibitor intermediatesAMGEN INC·Filed 2021·Granted Oct 14, 2025·0 cites·62 claims
- 2150US8501954B2Asymmetric process for making substituted 2-amino-thiazolonesCAILLE SEB·Filed 2009·Granted Aug 6, 2013·0 cites·5 claims
- 2249US2023183164A1Synthesis of Vinyl Cyclobutyl IntermediatesAMGEN INC·Filed 2021·Application pending·0 cites
- 2349US2024002400A1Enantioselective alkenylation of aldehydesAMGEN INC·Filed 2021·Application pending·0 cites
- 2446US2013345432A1Asymmetric process for making substituted 2-amino-thiazolonesAMGEN INC·Filed 2013·Application pending·0 cites
- 2545US2025186442A1Obicetrapib and Ezetimibe Combination Treatment and Fixed Dose Pharmaceutical CompositionsNEWAMSTERDAM PHARMA B V·Filed 2025·Application pending·0 cites
- 2640US2023117777A1Methylation of mcl-1 compoundsAMGEN INC·Filed 2021·Application pending·0 cites
- 2738US11708341B2Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereofAMGEN INC·Filed 2017·Granted Jul 25, 2023·0 cites·28 claims
- 2838US10858389B2Solution phase method for preparing etelcalcetideAMGEN INC·Filed 2016·Granted Dec 8, 2020·0 cites·19 claims
Join the waitlist — get patent alerts
Get an alert when Sheng Cui files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →